An assessment of cholesterol goal attainment in patients with chronic kidney disease

Journal of Clinical Lipidology

Volumn 4, Issue 4, 2010, Pages 298-304

  Stadler, Sheila L ^a,b   Bhardwaja, Bharati ^a,b   Olson, Kari L ^a,b   Powers, J David ^a   Lanese, Diane ^a  

^a KAISER PERMANENTE   (United States)

^b UNIVERSITY OF COLORADO   (United States)

Author keywords

Chronic kidney disease; Goal attainment; LDL cholesterol; Lipids; Statins

Indexed keywords

ANTILIPEMIC AGENT; CHOLESTEROL; EZETIMIBE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; LOW DENSITY LIPOPROTEIN CHOLESTEROL;

ADULT; AGED; ARTICLE; CHRONIC KIDNEY DISEASE; CONTROLLED STUDY; DIABETES MELLITUS; FEMALE; GENDER; GLOMERULUS FILTRATION; HUMAN; LIPID ANALYSIS; MAJOR CLINICAL STUDY; MALE; PRACTICE GUIDELINE; PRIORITY JOURNAL; AGE; BLOOD; CARDIOVASCULAR DISEASE; CHRONIC DISEASE; CROSS-SECTIONAL STUDY; GLOMERULUS FILTRATION RATE; KIDNEY DISEASE; MIDDLE AGED; REGRESSION ANALYSIS; RENAL REPLACEMENT THERAPY; RISK FACTOR; SEX DIFFERENCE;

AGE FACTORS; AGED; AGED, 80 AND OVER; CARDIOVASCULAR DISEASES; CHOLESTEROL, LDL; CHRONIC DISEASE; CROSS-SECTIONAL STUDIES; FEMALE; GLOMERULAR FILTRATION RATE; HUMANS; HYPOLIPIDEMIC AGENTS; KIDNEY DISEASES; MALE; MIDDLE AGED; PRACTICE GUIDELINES AS TOPIC; REGRESSION ANALYSIS; RENAL DIALYSIS; RISK FACTORS; SEX FACTORS;

EID: 79959574235     PISSN: 19332874     EISSN: 18764789     Source Type: Journal    
DOI: 10.1016/j.jacl.2010.06.005     Document Type: Article

References (37)

1. Collins AJ, Foley RN, Herzog C, et al. United States Renal Data System 2008 Annual Data Report. Am J Kidney Dis. 2009;53:S1-S374.
2. K/DOQI Clinical Practice Guidelines for Managing Dyslipidemias in Chronic Kidney Disease. Am J Kidney Dis. 2003;41:S1-S91.
3. Levey AS, Beto JA, Coronado BE, et al. Controlling the epidemic of cardiovascular disease in chronic renal disease: What do we know? What do we need to learn? Where do we go from here? National Kidney Foundation Task Force on Cardiovascular Disease. Am J Kidney Dis. 1998;32:853-906.
4. Muntner P, He J, Hamm L, Loria C, Whelton PK. Renal insufficiency and subsequent death resulting from cardiovascular disease in the United States. J Am Soc Nephrol. 2002;13:745-753.
5. Eknoyan G. On the epidemic of cardiovascular disease in patients with chronic renal disease and progressive renal failure: A first step to improve the outcomes. Am J Kidney Dis. 1998;32:S1-S4.
6. Go AS, Chertow GM, Fan D, McCulloch CE, Hsu CY. Chronic kidney disease and the risks of death, cardiovascular events, and hospitalization. N Engl J Med. 2004;351:1296-1305.
7. Bakris GL, Williams M, Dworkin L, et al. Preserving renal function in adults with hypertension and diabetes: A consensus approach. National Kidney Foundation Hypertension and Diabetes Executive Committees Working Group. Am J Kidney Dis. 2000;36:646-661.
8. Schiffrin EL, Lipman ML, Mann JF. Chronic kidney disease: Effects on the cardiovascular system. Circulation. 2007;116:85-97.
9. Parikh NI, Hwang SJ, Larson MG, Meigs JB, Levy D, Fox CS. Cardiovascular disease risk factors in chronic kidney disease: Overall burden and rates of treatment and control. Arch Intern Med. 2006; 166:1884-1891.
10. Sarnak MJ, Levey AS, Schoolwerth AC, et al. Kidney disease as a risk factor for development of cardiovascular disease: A statement from the American Heart Association Councils on Kidney in Cardiovascular Disease, High Blood Pressure Research, Clinical Cardiology, and Epidemiology and Prevention. Hypertension. 2003;42: 1050-1065.
11. Levin A, Thompson CR, Ethier J, et al. Left ventricular mass index increase in early renal disease: Impact of decline in hemoglobin. Am J Kidney Dis. 1999;34:125-134.
12. Muntner P, Hamm LL, Kusek JW, Chen J, Whelton PK, He J. The prevalence of nontraditional risk factors for coronary heart disease in patients with chronic kidney disease. Ann Intern Med. 2004;140: 9-17.
13. Shlipak MG, Fried LF, Crump C, et al. Elevations of inflammatory and procoagulant biomarkers in elderly persons with renal insufficiency. Circulation. 2003;107:87-92.
14. Eknoyan G, Lindberg JS. On the evolving nature of understanding dialysis-related disorders. Am J Kidney Dis. 2003;41:S1-S3.
15. Stamler J, Wentworth D, Neaton JD. Is relationship between serum cholesterol and risk of premature death from coronary heart disease continuous and graded? Findings in 356,222 primary screenees of the Multiple Risk Factor Intervention Trial (MRFIT). JAMA. 1986; 256:2823-2828.
16. Anderson KM, Castelli WP, Levy D. Cholesterol and mortality. 30 years of follow-up from the Framingham study. JAMA. 1987;257: 2176-2180.
17. Grundy SM, Cleeman JI, Merz CN, et al. Implications of recent clinical trials for the National Cholesterol Education Program Adult Treatment Panel III guidelines. Circulation. 2004;110:227-239.
18. Executive Summary of The Third Report of The National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, And Treatment of High Blood Cholesterol In Adults (Adult Treatment Panel III). JAMA. 2001;285:2486-2497.
19. Briganti EM, Kerr PG, Shaw JE, Zimmet PZ, Atkins RC. Prevalence and treatment of cardiovascular disease and traditional risk factors in Australian adults with renal insufficiency. Nephrology (Carlton). 2005;10:40-47.
20. Tonelli M, Bohm C, Pandeya S, Gill J, Levin A, Kiberd BA. Cardiac risk factors and the use of cardioprotective medications in patients with chronic renal insufficiency. Am J Kidney Dis. 2001;37: 484-489.
21. Lenz O, Mekala DP, Patel DV, Fornoni A, Metz D, Roth D. Barriers to successful care for chronic kidney disease. BMC Nephrol. 2005;6:11.
22. Von KM, Wagner EH, Saunders K. A chronic disease score from automated pharmacy data. J Clin Epidemiol. 1992;45:197-203.
23. Pearson TA, Laurora I, Chu H, Kafonek S. The lipid treatment assessment project (L-TAP): A multicenter survey to evaluate the percentages of dyslipidemic patients receiving lipid-lowering therapy and achieving low-density lipoprotein cholesterol goals. Arch Intern Med. 2000;160:459-467.
24. Waters DD, Brotons C, Chiang CW, et al. Lipid treatment assessment project 2: A multinational survey to evaluate the proportion of patients achieving low-density lipoprotein cholesterol goals. Circulation. 2009; 120:28-34.
25. Olson KL, Rasmussen J, Sandhoff BG, Merenich JA. Lipid management in patients with coronary artery disease by a clinical pharmacy service in a group model health maintenance organization. Arch Intern Med. 2005;165:49-54.
26. Yan AT, Yan RT, Tan M, et al. Contemporary management of dyslipidemia in high-risk patients: Targets still not met. Am J Med. 2006;119: 676-683.
27. Tran MT, Billups SJ. Can guideline adherence be improved by letter outreach? Diabetes Care. 2008;31:e22.
28. Heart Protection Study Collaborative Group. MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20,536 high-risk individuals: A randomised placebo-controlled trial. Lancet. 2002;360: 7-22.
29. Kausz AT, Khan SS, Abichandani R, et al. Management of patients with chronic renal insufficiency in the Northeastern United States. J Am Soc Nephrol. 2001;12:1501-1507.
30. Ghandehari H, Kamal-Bahl S, Wong ND. Prevalence and extent of dyslipidemia and recommended lipid levels in US adults with and without cardiovascular comorbidities: The National Health and Nutrition Examination Survey 2003-2004. Am Heart J. 2008;156: 112-119.
31. KDOQI Clinical Practice Guidelines and Clinical Practice Recommendations for Diabetes and Chronic Kidney Disease. Am J Kidney Dis. 2007;49:S12-S154.
32. Shepherd J, Kastelein JJ, Bittner V, et al. Intensive lipid lowering with atorvastatin in patients with coronary heart disease and chronic kidney disease: The TNT (Treating to New Targets) study. J Am Coll Cardiol. 2008;51:1448-1454.
33. Wanner C, Krane V, Marz W, et al. Atorvastatin in patients with type 2 diabetes mellitus undergoing hemodialysis. N Engl J Med. 2005;353: 238-248.
34. Fellstrom BC, Jardine AG, Schmieder RE, et al. Rosuvastatin and cardiovascular events in patients undergoing hemodialysis. N Engl J Med. 2009;360:1395-1407.
35. Collins R, Armitage J, Parish S, Sleigh P, Peto R. MRC/BHF Heart Protection Study of cholesterol-lowering with simvastatin in 5963 people with diabetes: A randomised placebo-controlled trial. Lancet. 2003;361:2005-2016.
36. Athyros VG, Mikhailidis DP, Papageorgiou AA, et al. The effect of statins versus untreated dyslipidaemia on renal function in patients with coronary heart disease. A subgroup analysis of the Greek atorvastatin and coronary heart disease evaluation (GREACE) study. J Clin Pathol. 2004;57:728-734.
37. Tonelli M, Isles C, Craven T, et al. Effect of pravastatin on rate of kidney function loss in people with or at risk for coronary disease. Circulation. 2005;112:171-178.